Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: 4toSchool, Go-Gold, TheHungryHippo, BluSkies, Rdy1
Search This Board: 
Last Post: 7/23/2017 1:37:27 PM - Followers: 850 - Board type: Free - Posts Today: 28


US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director



About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here:  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here:

USRM - Daily Candlesticks


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: Quarterly Report (10-q) 05/02/2017 04:06:21 PM
USRM News: Significant Updates on the Following Companies and New Coverage 04/20/2017 09:00:00 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:49:04 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:47:59 AM
USRM News: Statement of Changes in Beneficial Ownership (4) 03/31/2017 04:02:24 PM
#72779  Sticky Note NASA is conducting Cardiac Stem Cell Therapy studies caltr0m 06/30/17 08:34:16 AM
#72621  Sticky Note MYOCELL CLINICAL TRIALS, SIX PATIENT DEATHS !! Hornet Driver 06/29/17 10:22:27 AM
#71576  Sticky Note QUOTE LOL, Hippo DD info found here! sdave2002 06/22/17 03:42:36 PM
#70057  Sticky Note CEO Blog: June is TheHungryHippo 06/18/17 10:57:39 PM
#74329   No doubt ! Look at the market BurningMan 07/23/17 01:37:27 PM
#74328   USRM= diamond in the rough! Staypositive1 07/23/17 01:36:01 PM
#74327   You are so wrong ! Micro cap guys BurningMan 07/23/17 12:50:39 PM
#74325   The only investors money that will come into Ryguy008 07/23/17 11:57:33 AM
#74324   USRM is not diamond in the rough Ryguy008 07/23/17 11:54:45 AM
#74322   USRM: OTC's Diamond in the Rough! GetRichorGetHighTryn 07/23/17 11:20:18 AM
#74321   EVERYONE HERE knows regenerative medicine is going to MyzStreet 07/23/17 10:52:45 AM
#74319   Still somebody has yet to prove me wrong Ryguy008 07/23/17 10:34:15 AM
#74313   What? I don't understand. Please elaborate for us Zues 07/23/17 07:11:03 AM
#74312   When this stock inevitably goes above $1, GetRichorGetHighTryn 07/23/17 07:08:16 AM
#74309   ''The stem cell market is expected to reach emit 07/23/17 02:52:33 AM
#74306   Not to mention... still no news from US Ryguy008 07/23/17 02:20:58 AM
#74305   Seriously tho.., who keeps adding a stock that Ryguy008 07/23/17 02:13:19 AM
#74303   Seriously? This isn't the diamond in the rough, snax 07/23/17 12:51:05 AM
#74302   Ya man the whole thing is crashing down. Zues 07/23/17 12:00:14 AM
#74300   On the beach right now sippin my usrm GoldenMind 07/22/17 11:09:37 PM
#74296   Rocket, you want to match my buys tomarrow? Demono 07/22/17 09:28:57 PM
#74295   Ya man the whole thing is in down 2231663 07/22/17 09:17:42 PM
#74294   Quote LOL, ""Kuwait-based High Rising Group to launch Hornet Driver 07/22/17 09:03:19 PM
#74291   "Kuwait-based High Rising Group to launch U. S. Ryguy008 07/22/17 07:41:25 PM
#74290   True but this is all about potential and BurningMan 07/22/17 05:52:40 PM
#74289   True, but that's just not a lot of revenue. emit 07/22/17 05:39:30 PM
#74286   Why don't you give us all a few a1tellem 07/22/17 02:01:53 PM
#74285   Very rare. They are tapping into the BurningMan 07/22/17 11:04:23 AM
#74284   47. Most of you know what it GetRichorGetHighTryn 07/22/17 10:34:27 AM
#74282   Revenue up by 62% from $710,000 in Q1 MyzStreet 07/22/17 09:35:44 AM
#74281   You are right tho on this last one. Ryguy008 07/22/17 08:07:11 AM
#74280   USRM was cash-flow positive, do you understand what 4toSchool 07/22/17 03:04:19 AM
#74279   We need to set up shop in Texas emit 07/22/17 12:39:55 AM
#74278   Its coming :) GoldenMind 07/22/17 12:31:01 AM
#74277   Hmmm -- emit 07/22/17 12:11:05 AM
#74276   ''As of 2017, the U.S. healthcare system is emit 07/21/17 11:52:01 PM
#74275   Note in the Comments: emit 07/21/17 11:33:09 PM
#74274   Good comprehensive read of overall industry. Yup we emit 07/21/17 11:28:50 PM
#74273   Moma Meia that's a lota doe for fatty emit 07/21/17 11:15:18 PM
#74272   32 Days Ago We Were Told That They emit 07/21/17 10:57:30 PM
#74271   It's Alive! It's Alive! emit 07/21/17 10:39:46 PM
#74270   Yep. The ones I am in I got Gotham Bay Group 07/21/17 10:28:35 PM
#74269   Are you sure you said that right? emit 07/21/17 10:22:06 PM
#74267   Every penny stock ever dilutes at some level. BurningMan 07/21/17 08:31:02 PM
#74266   Maybe it goes down some, maybe it goes MGrubby29 07/21/17 08:27:40 PM
#74263   STEM CELLS CAN BE USED FOR THOUSANDS OF 0mn1 07/21/17 07:18:02 PM
#74262   We all know deep down, there is gonna Ryguy008 07/21/17 06:33:43 PM
#74261   Hope all the selling is done, next week Go-Gold 07/21/17 05:59:58 PM
#74258   Some people here need to understabd this is GoldenMind 07/21/17 04:35:26 PM
#74256   Personal analysis still correct. Last week at the Ryguy008 07/21/17 04:11:11 PM
#74252   SEC GOING CONCERN WARNINGS, LIQUIDITY PROBLEMS !! Hornet Driver 07/21/17 03:43:37 PM
#74251   Finally someone that knows that they cant answer Staypositive1 07/21/17 02:47:13 PM
#74250   Of course I do. We have been working Gotham Bay Group 07/21/17 02:43:15 PM
#74248   Have fun losing it... still holding my free Ryguy008 07/21/17 02:29:32 PM